Clinical trial
A Multi-center, Prospective, Observational Study to Evaluate the Safety and Efficacy of Kremezin IDT/Fine Gran in Progressive Chronic Kidney Disease Patients.
NCT07930169 is registered in ClinicalTrials.gov with HK inno.N Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Prospective, Observational Study to Evaluate the Safety and Efficacy of Kremezin IDT/Fine Gran in Progressive Chronic Kidney Disease Patients.
- Lead sponsor
- HK inno.N Corporation
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- July 18, 2023
- Completion date
- December 31, 2027
- Enrollment
- 3,125 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic kidney disease
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Proportion of participants with an effective overall assessment at Week 24
Overall effectiveness will be assessed by the investigator based on serum creatinine (Scr) and estimated glomerular filtration rate (eGFR). Participants will be classified as effective, ineffective, or unevaluable; unevaluable participants will be excluded from the analysis.
Lead sponsor's other trials
HK inno.N Corporation, most recent start first.
+98 more trials See the organization page
Similar trials
Same condition (Renal Insufficiency, Chronic) and phase, most recent start first.
+856 more trials See the condition page